Randomised controlled trial · 2019
Randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of benzocaine wipes in subjects with premature ejaculation
Shabsigh R, Perelman MA, Getzenberg RH, Grant A, Kaminetsky J (2019). Randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of benzocaine wipes in subjects with premature ejaculation. Journal of Men's Health. doi:10.22374/jomh.v15i3.156
In a small single-centre trial funded by the wipe's maker (26 men with complete data), 4% benzocaine wipes raised mean latency to 164.8 s after one month versus 110.1 s on placebo; two men reported mild side effects.
Summary
Delay wipes are single-use towelettes soaked in a liquid containing a local anaesthetic. This trial tested PREBOOST wipes, which contain 4% benzocaine in water, alcohol and propylene glycol. One wipe was applied to the glans (head) and shaft of the penis and left to dry before intercourse. The placebo wipes contained the same liquid without benzocaine.
Men aged 18 or over with premature ejaculation (PE) by DSM-IV criteria, in a stable heterosexual relationship and with an average intravaginal ejaculatory latency time (IELT: the time from penetration to ejaculation) of 2 minutes or less over at least four stopwatch-timed encounters, were randomized 2:1 to benzocaine or placebo wipes for one month. Men with erectile dysfunction were excluded. An open-label month followed, in which the placebo group switched to the active wipes.
The paper analyses men with complete follow-up data (17 on benzocaine, 9 on placebo). After the blinded month, mean IELT was 164.8 seconds with benzocaine and 110.1 seconds with placebo (P = 0.007). After a second, open-label month, the benzocaine group's mean IELT was 329.7 seconds. In the blinded month, 13 of 17 men on benzocaine and 3 of 9 on placebo met the trial's 120-second responder threshold (the paper describes it both as an improvement of 120 seconds and as reaching a latency of 2 minutes). Scores for sexual satisfaction and distress on the Index of Premature Ejaculation improved more with benzocaine; the improvement in control did not reach statistical significance. Two men on benzocaine reported adverse events (a mild headache with back pain, and mild penile irritation), and no transfer to partners was reported.
Limitations
The study was financially supported by Veru Inc., which sold the PREBOOST wipes; two authors were consultants to the company and the principal investigator was paid to run the trial. It was a single-centre study with very few participants, and the paper's counts are inconsistent (it mentions 21 randomized men, then 17 and 9). The second-month figure of 329.7 seconds comes from an open-label phase without a blinded comparison, so expectation may account for part of it. The journal is not indexed in PubMed, and no independent replication has been published.
What it means for you
A 4% benzocaine wipe produced a modest average gain over a placebo wipe, under a minute in the blinded comparison, in a small manufacturer-funded trial. That is consistent with what other numbing products achieve, but it is weak evidence on its own. If you try wipes, follow the label, let the product dry before contact, and treat them as a short-term aid rather than a fix.